MSN Laboratories receives Central Drugs Standard Control Organisation approval for generic Semaglutide 

Key Highlights: 

• MSN Laboratories has received approval from the Central Drugs Standard Control Organisation to manufacture and market a generic version of Semaglutide in India. 

• The company plans to launch the therapy by the end of March 2026, aligning with the anticipated entry of generic semaglutide into the Indian market following key patent expiries. The treatment is widely used in the management of Type 2 Diabetes and is gaining global attention for its role in metabolic health. 

• MSN Laboratories aims to leverage its expertise in complex peptide manufacturing and integrated R&D capabilities to deliver an affordable alternative, expanding patient access to advanced metabolic therapies while supporting the growing demand for diabetes treatment in India.  

Implications:  

MSN joins the generics stampede, slashing premium GLP-1 prices and handing endocrinologists budget-friendly options for mass diabetes management. 
Integrated R&D gives MSN edge in rapid scale-up, stealing share from late-moving rivals as Tier-2 clinics embrace advanced therapies. 
Multiple generic semaglutide launches reshape metabolic treatment landscape, accelerating adoption across price-sensitive patient segments nationwide. 

Source: Pharmabiz | Image: MSN